These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37209991)

  • 1. Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model.
    Tseng LM; Lau KY; Chen JL; Chu PY; Huang TT; Lee CH; Wang WL; Chang YY; Huang CT; Huang CC; Chao TC; Tsai YF; Lai JI; Dai MS; Liu CY
    Exp Cell Res; 2023 Aug; 429(1):113652. PubMed ID: 37209991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A marine-derived small molecule induces immunogenic cell death against triple-negative breast cancer through ER stress-CHOP pathway.
    Wen H; Zhong Y; Yin Y; Qin K; Yang L; Li D; Yu W; Yang C; Deng Z; Hong K
    Int J Biol Sci; 2022; 18(7):2898-2913. PubMed ID: 35541893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
    Su JC; Mar AC; Wu SH; Tai WT; Chu PY; Wu CY; Tseng LM; Lee TC; Chen KF; Liu CY; Chiu HC; Shiau CW
    Sci Rep; 2016 Jul; 6():28888. PubMed ID: 27364975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
    Wang Z; Cordova LE; Chalasani P; Lu J
    Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
    Li Y; Zhang H; Li Q; Zou P; Huang X; Wu C; Tan L
    Cancer Lett; 2020 Dec; 495():12-21. PubMed ID: 32941949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hainanenin-1, an oncolytic peptide, triggers immunogenic cell death via STING activation in triple-negative breast cancer.
    Li X; Su N; Yu H; Li X; Sun SL
    Cell Commun Signal; 2024 Jul; 22(1):352. PubMed ID: 38970078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8
    Shan CK; Du YB; Zhai XT; Wang YX; Li Y; Gong JH; Ge ZJ; Liu XJ; Zhen YS
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):425-436. PubMed ID: 33388950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Dual-Targeting Liposome Enhances Triple-Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation.
    Luo K; Yang L; Yan C; Zhao Y; Li Q; Liu X; Xie L; Sun Q; Li X
    Small; 2023 Oct; 19(40):e2302834. PubMed ID: 37264710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
    Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
    J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
    Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
    BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
    Hossain DMS; Javaid S; Cai M; Zhang C; Sawant A; Hinton M; Sathe M; Grein J; Blumenschein W; Pinheiro EM; Chackerian A
    J Clin Invest; 2018 Feb; 128(2):644-654. PubMed ID: 29337311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
    Gao M; Wang T; Ji L; Bai S; Tian L; Song H
    Front Immunol; 2020; 11():366. PubMed ID: 32194569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
    Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
    Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
    Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.